Clinical Trials
3 trialsNCT02325739 2024-10-21
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Novartis
Phase 1/2 Completed
NCT06298123 2024-03-07
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
Tongji Hospital
Completed
NCT02988440 2020-12-19
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Novartis
Phase 1 Completed